Introduction
The world is facing a rapidly worsening crisis related to the rise in rates of resistance of bacterial pathogens to available therapeutic antimicrobial agents. As no fundamentally new classes of antibiotics have been discovered in recent decades, treatment of infections must currently rely on the available agents. However, infection-producing bacteria are increasingly developing resistance to many routinely used antibiotic groups, and even to 'last resort' agents. The spread of antibioticresistant bacteria has led many experts to declare this issue one of the world's most pressing public health problems. 1 It is thus time to review and improve how antimicrobials are used for all types of clinical problems, including for various types of wounds.
Why we need antimicrobial stewardship
Factors contributing to the growth of antibiotic resistance are complex, but clearly the rate of antibiotic resistance is directly related to the level of antibiotic use. This document is concerned only with clinical prescribing for humans, an area over which clinicians have more control and in which improvements may occur relatively quickly. Clinicians, as well as the public, must understand that antibiotic consumption is associated with the development of antibiotic resistance at not only the individual patient level, but also at community, national and regional levels. 2 Prior treatment of a patient with commonly used antibiotics greatly increases that person's risk of infection with an antibiotic-resistant organism, which is directly responsible for increases in morbidity, length of hospitalization, mortality and cost of healthcare. 3, 4 # The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com Studies across the globe have consistently revealed that about 80% of antibiotic courses, and 20% of all antibiotics administered, are prescribed in the community or ambulatory setting. In both the outpatient and inpatient settings, up to 50% of these treatment courses are unnecessary or inappropriate.
5 Table 1 summarizes some of the key factors specifically contributing to antimicrobial misuse in patients with wounds. In addition to driving resistance, inappropriate antibiotic prescribing is associated with avoidable drug-related adverse events, other collateral ecological damage such as Clostridium difficile disease, and unnecessary financial costs. The rate of antibiotic misuse in long-term care facilities, where highly vulnerable patients with wounds frequently reside, may be especially high. 6 These data highlight the urgent need for more prudent antibiotic prescribing, both for prophylaxis and treatment. Antibiotics are perhaps the only drugs that inevitably become less effective with use, and that have potential adverse effects on persons for whom they are not prescribed. Thus, the concept of 'stewardship', the ethical and responsible planning and management of a resource, has gained clinical, political and governmental traction over the last decade. Antimicrobial stewardship (AMS) is an interprofessional effort across the continuum of a patient's care that involves timely and optimal selection of antimicrobial agents, their doses and the duration of their use; the aim is to achieve the best clinical outcome with minimal toxicity to the patient and the environment. 7 AMS programmes have been shown to achieve these aims, especially if they obtain commitment from organization leaders, seek accountability for actions and outcomes, include members with antibiotic agent expertise, actively engage in implementing changes, track and report the outcomes of these actions, and educate all involved healthcare workers and patients about the optimal use of antimicrobials. 8 In a range of settings implementing an AMS programme has been associated with reduced rates of antibiotic resistance, fewer C. difficile infections, better clinical outcomes and lower financial costs. 9 -11 In simple terms AMS generally includes: (i) avoiding prescribing antimicrobials when they are not indicated (e.g. a non-infectious problem or a non-bacterial infection); (ii) prescribing an appropriate regimen when antimicrobial therapy is indicated [i.e. the narrowest spectrum for the likely or proven pathogen(s)]; (iii) ordering therapy for the correct duration (i.e. just long enough to achieve resolution of the signs and symptoms used to diagnose infection), at the optimal dose and by the appropriate route; and (iv) using an agent that has the least risk for adverse effects for the patient and the community (see Table 2 ). 12 It is also clear that improving antibiotic use will require increased accountability and transparency at the societal level. 13 There are two main types of approaches to AMS. Persuasive methods, aimed at educating the clinician and encouraging optimal treatment, broadly advise clinicians about how to prescribe, or give feedback on their prescribing. Restrictive methods, on the contrary, administratively constrain how clinicians may prescribe, such as by limiting access to specific antibiotic agents, or by instituting automatic stop orders or time limits for antibiotic treatments. One hybrid type of intervention encourages all clinicians to take an 'antibiotic time-out' about 48 h after prescribing a regimen to review whether or not the patient has an infection, if they are on the most appropriate antibiotic regimen and for how long the therapy should continue. A meta-analysis of 89 studies from 19 countries found that each approach could improve prescribing, reduce antibiotic resistance and decrease the number of hospitalacquired infections. 9 Available data suggest that persuasive interventions are less effective in the short term than restrictive methods, but may have a greater long-term effect on prescribing practices.
Unfortunately, available studies of AMS interventions provide few data on potential harms of the programme, long-term sustainability, or which of the multiple components are the most important. Furthermore, most studies of AMS programmes are reported from resource-rich settings and inpatient facilities, but evidence of their effectiveness in outpatient settings where most antibiotic prescribing occurs is emerging.
14 AMS interventions are most useful when determined by the type, scale and context of the problems uncovered by audits. The 'Start Smart and Then Focus' programme promulgated by Public Health England provides an algorithmic approach, which may be helpful in engaging clinicians in daily stewardship activity and can be adopted or adapted (as we have done in Figure 1 ) to the local clinical, geographical and healthcare setting. 15 Whilst the AMS approach is generic to prescribing for all types of infections, a range of recommendations has been developed for specific syndromes. Although skin and soft tissue infections are among the most common for which antibiotics are prescribed, we have been unable to find any published guidance for prudent antimicrobial therapy practice for this indication. In particular, we know of no guidelines for the subset of patients with infected wounds, which represent a huge clinical and economic burden and pose special problems both in diagnosis and treatment. For example, wound infections are frequently polymicrobial, thus requiring broad-spectrum antimicrobial regimens, and most wounds take many weeks (or even months) to heal. Some clinicians think that they should continue antibiotic therapy until healing occurs, but no evidence supports this belief. 16 Furthermore, because wounds are frequently recurrently infected, these patients are often exposed to repeated courses of therapy. 
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A study in Sweden, where the consensus is to restrict antibiotic therapy of wounds, found that among 707 patients seen in various inpatient and outpatient settings, 27% were receiving systemic antibiotic therapy, a rate of antibiotic therapy over 10 times higher than that for the whole population of the study region. 18 Another report from Sweden, where a mandatory national registry of ulcer treatment was subsequently established, 19 documented widespread unnecessary use of systemic antibiotics in the management of chronic wounds. But, instituting the registry led to a reduction in patients receiving antibiotic treatment for these wounds from 71% to 29%. 19 In preparing this document we assembled a multidisciplinary group with experience in wound infections to develop pragmatic guidance on optimizing antimicrobial therapies for wounds. This guidance is not intended to be a comprehensive or systematic review of the literature, nor a set of highly regimented recommendations. Rather, it is a joint, interdisciplinary undertaking of the European Wound Management Association (EWMA) and the British Society for Antimicrobial Chemotherapy (BSAC) that aims to use well-established principles of wound management, antibiotic treatment and stewardship to provide practical guidance to the various primary care and specialty clinicians and the extended healthcare team who treat patients with any type of wound.
Who should be involved in AMS for wounds?
Teams: AMS and wound care
When possible, an interdisciplinary team of specialists should undertake AMS. In the hospital setting this usually includes an infectious diseases physician or clinical microbiologist, an infection control manager and a pharmacist. The team should develop institutional policies, while also recommending best-treatment options for individual patients. The idea of an AMS team is not new, 20 but the rules for how it will run differ based on the institution's needs and resources. Unfortunately, these teams are infrequently available in the outpatient setting. AMS teams often work in conjunction with a team devoted to improving wound care, often for pressure or diabetic foot ulcers. These wound teams usually comprise clinicians (e.g. specialized nurses, physicians and surgeons), microbiologists, pharmacists, prosthetists/orthotists and others. The specific training of the individual is often less important than their enthusiasm for the team's goals. The activities and structure of any team must be flexible and function within constraints imposed by other hospital activities.
Given the variety and frequent changeover of clinicians who may care for a patient, wound care teams must devise a method (preferably electronic, with standardized measurements and photographs) to document the wound's status and the team's plan of care. The benefits of teamwork can be undermined by interprofessional rivalries and miscommunication, sometimes related to a lack of commonly agreed terminology. Members of the AMS programme must maintain their own education in the field as well as impart up-to-date knowledge to other clinicians and to patients.
Patients
Healthcare workers must remember that the patient is a crucial member of the teams caring for them. The clinicians must both educate and empower the patient (or a responsible caregiver) to ensure they understand and agree with the treatment plan. The patient must be initially, then continually, apprised of the issues related to wound care during the course of treatment. Unfortunately, many patients have come to believe that antibiotic therapy is beneficial, even necessary, for treating their wounds. If the clinician suggests otherwise there is the potential for conflict 
Review and reduced patient satisfaction with their care. 21 While the clinician may decide to give in to the patient's expectation, experience suggests that most patients will respond positively to reassurance and an explanation that for their wound the risks of antibiotic therapy (both for them, and for society as a whole) are greater than any potential benefits. Patients should also be encouraged to inform their clinicians about any treatments (including antimicrobials not prescribed to them for this wound, or over-the-counter or folk remedies) they have recently used and any problems they think they may have in adhering to the treatment plan.
Clinicians
We used the term 'clinician' to describe any healthcare professional who has been educated, trained and certified to provide direct patient care. Their key goals in treating a wound are relieving discomfort, eradicating any infection and accelerating wound healing, while avoiding adverse effects, controlling costs, forestalling re-infection, and averting administrative or legal censure for failing to meet the 'standard of care' with their treatment. In some countries specially trained non-medical-doctor clinicians, e.g. podiatrists/chiropodists, advanced practice nurses or pharmacists, can prescribe antibiotic therapy, but access to antiseptics is usually unrestricted.
How to conduct AMS for patients with wounds
Even in centres that have an AMS team, any healthcare worker who deals with wounds should be familiar with the basic principles of this process. To this end, it is essential that all clinicians caring for patients with wounds know how to accurately diagnose the presence or absence of infection. In complex cases or with patients with comorbidities, it may be helpful for an inexperienced clinician to seek consultation for this task from a wound specialist. Clinicians should, of course, make antimicrobial prescribing decisions in individual patients in the context of the broader AMS programme, as well as in collaboration with other hospital or outpatient clinical management teams. 22, 23 Figure 1 presents a simplified algorithmic approach for antimicrobial therapy of wounds.
Diagnosing infection
The treating clinician should assess for the presence of local or systemic evidence of infection at the first, and every subsequent, wound assessment. Wound infection is primarily diagnosed by clinical findings, usually supported by microbiological data. Culturing clinically infected wounds is helpful to define the pathogens present and their antibiotic susceptibilities. Clinicians should not, however, prescribe antibiotics just because organisms grow from a wound culture, as all open wounds become colonized.
The key diagnostic features of wound infection are the classic signs of inflammation: redness or erythema (rubor), warmth (calor); swelling or induration (tumor); pain or tenderness (dolor); and, pus or purulent secretions. Neuropathy, vascular insufficiency and various types of immunodeficiency may be associated with abnormal local inflammatory responses, thus potentially masking (or mimicking) these diagnostic findings. In these settings, it may be necessary to assess so-called 'secondary' or 'intermediate' signs and symptoms suggesting wound infection, such as friable or discoloured granulation tissue, pocketing, undermining of the ulcer rim or foul odour. Systemic signs or symptoms (e.g. fever, chills, altered mentation) or elevated inflammatory markers (e.g. leukocytes, C-reactive protein, erythrocyte sedimentation rate) are often absent with a wound infection. Clinicians must seek any evidence of underlying deep tissue infection (e.g. of muscle, tendon, joint, bone), as well as involvement of any prosthetic or implanted material, as these usually require surgical 
Specimen collection
There is generally no need to culture a clinically uninfected wound, as these do not require antimicrobial therapy. All clinically infected wounds should be cultured, however, preferably by obtaining tissue (either by curettage or biopsy), which provides more sensitive and specific results than swabbing 24, 25 To lessen the likelihood of identifying colonizers (rather than pathogens), clinicians should cleanse (with a non-bactericidal agent) and debride the wound before collecting a specimen for culture. Managers should remove organizational barriers to tissue sampling, e.g. lack of required collection and transport equipment, or of a clinician with sampling expertise. To avoid false-negative cultures, it is best (if possible) to collect a specimen for culture before starting antibiotic therapy. The advantages of avoiding inappropriate antimicrobial therapy by proper wound sampling outweigh any potential increase in short-term organizational costs. For a patient exhibiting signs of systemic inflammatory response syndrome the clinician should order blood cultures. Although wound infections are infrequently associated with bacteraemia, if present it usually requires hospitalization, along with intravenous and longer duration antibiotic therapy. 26 When there is suspicion that a wound may be complicated by osteomyelitis the clinician should consider obtaining a bone culture. These often reveal different results (usually fewer pathogens) than cultures of superficial or even deep soft tissue.
Specimen processing and reporting
Once collected, the specimen for culture must be rapidly and properly transported to the clinical microbiology laboratory, accompanied by key clinical details, especially regarding recent or current antibiotic therapy. The laboratory must process the specimen quickly and report the results in understandable language. Some laboratories reasonably believe that to reduce the likelihood of inappropriate antibiotic therapy they should sometimes selectively restrict their reporting of isolated organisms or their antibiotic susceptibility results. 22 We believe that in settings where the clinician has, or has access to, expertise in clinical microbiology, laboratories should report all isolates from properly collected specimens. They should certainly report the presence of likely pathogenic organisms (e.g. S. aureus, b-haemolytic streptococci) and the susceptibility results for 'first line' antimicrobials against these (e.g. semi-synthetic penicillins and macrolides). Susceptibility to advanced-generation cephalosporins or broaderspectrum penicillin/b-lactamase inhibitor combinations might be 'suppressed', to discourage their unnecessary use. Although any organism isolated from a properly collected specimen may be a pathogen, it may be appropriate for clinical microbiologists to suggest that some (e.g. corynebacteria, enterococci, coliforms, obligate anaerobes), especially if identified by highly sensitive molecular methods, are likely to be colonizers. Additional culture and susceptibility results should, of course, be available following discussion between the clinician and infection specialist.
Recently there have been reports of various molecular based techniques for diagnosis of bacterial infection in wounds. 27, 28 These may contribute to AMS by providing more rapid identification of causative pathogens, sometimes of their antibiotic resistance profiles, and perhaps the presence of virulence factors. 29 This potentially facilitates rapid selection of the most appropriate, narrowly targeted antibiotic regimen. However, while rapid molecular tests for pathogens to constrain unnecessary antibiotic therapy are useful for infections diagnosed microbiologically, they are less helpful for clinically diagnosed wound infections. Newer molecular microbiological techniques often disclose more pathogens than standard cultures, but we as yet do not know the clinical significance of this additional information. 30 
Indications for antibiotic therapy
A common antibiotic prescribing error is treating a patient with a superficial uninflamed wound from whom commensal bacteria are isolated (e.g. coagulase-negative Staphylococcus) or from whom clinically irrelevant bacteria or fungi (e.g. enterococci, coliforms or Candida) have 'overgrown' the wound during ongoing antibiotic therapy. No evidence supports that treatment with antibiotics in such situations either improves wound healing or prevents the development of clinical infection. 16 Microbiological investigations for a clinically uninfected wound are needed only when seeking evidence of colonization with an epidemiologically important pathogen (e.g. MRSA, VRE or carbapenemaseproducing Enterobacteriaceae). Knowing the carriage status of a patient at high risk for multidrug-resistant colonization may help determine the need for source isolation or short course decolonization therapy, or help select the appropriate therapy should the patient later develop evidence of wound infection. 31, 32 Approach to clinical management of wound infection
Empirical and definitive therapy
Antibiotic therapy is usually initially empirical, i.e. based on best guess of the causative pathogens and their antibiotic susceptibility, informed by available clinical and epidemiological data. Later definitive therapy is based on available culture and susceptibility results, and the clinical response to empirical therapy. Key factors in selecting empirical therapy include: the severity of the infection; any history suggesting likely pathogens (e.g. exposure to animals, recent travel, admission to a healthcare facility); recent antibiotic therapy; and knowing local antibiotic resistance data and the institution's AMS strategy. 33 The treating clinician should document the classification of the wound, the clinical severity of infection, and any diagnostic uncertainties and further diagnostic tests planned.
While risk stratification guidelines, such as those produced by the Infectious Diseases Society of America for skin and soft tissue infections, 31 MRSA 34 and diabetic foot infections, 35 are helpful, antimicrobial choices should be tailored to local circumstances. Empirical antibiotic therapy for virtually all infected wounds should be active against S. aureus (with consideration for the likelihood of MRSA), as it is the most commonly isolated pathogen in most settings. Additional coverage for other organisms (potentially including aerobic Gram-negative and anaerobic organisms) may be appropriate for severe infections or for patients with findings that suggest these organisms. Selecting an antibiotic regimen, including the dose and route of administration, depends on many factors. For an acute, severe (e.g. accompanied by sepsis or rapid progression) wound infection, intravenous therapy is usually appropriate, often with a combination of bactericidal agents. When the infection has clinically responded and microbiological results are available, consider simplification (narrowing the spectrum of therapy), changing from intravenous to oral ('switch') therapy with an agent with good orally bioavailability, or stopping therapy if an alternative (non-infectious) cause has been established. 13 The use of topical antimicrobials While systemic antibiotic therapy is appropriate for most clinically infected wounds, for superficial, mild infections topical antimicrobial (antibiotic and non-antibiotic) agents may have several potential benefits. 36 Most noteworthy: a small amount can achieve high levels directly at the site of infection; it avoids systemic adverse effects; and, it allows use of agents that cannot be administered systemically. There is much regional and geographical variation in the use of topical antibiotics, and in resistance rates of pathogens to these agents. We advise avoiding using antibiotics (as opposed to antiseptics) topically for treating wound infections as there is limited evidence of their effectiveness and they often select for resistant colonizing bacteria. Furthermore, topical treatment may cause peri-wound skin irritation, rash, eczema or impairment of wound healing. 37 Concerns also remain about possible cytotoxic effects of topical antimicrobials on the wound bed, especially with long-term treatment. 19, 36 A few topical antibiotics (e.g. fusidic acid, mupirocin, neomycin) may be appropriate to treat localized acute superficial skin infections, such as impetigo and folliculitis, but almost all other clinically infected wounds require systemic antibiotic therapy. 38, 39 Topical metronidazole may be beneficial in reducing wound odour, but the evidence is weak. 40 Non-antibiotic antimicrobials are widely used in wound care, notwithstanding the limited data supporting their usefulness. These include antiseptics (e.g. chlorhexidine, povidone or cadexomer iodine), heavy metals [e.g. silver, mercury (mercurochrome)] and natural products (e.g. honey, charcoal). Topical antimicrobials may be helpful where there is localized infection of chronic wounds, 37 although some antiseptics may delay healing. 36, 38 For wounds with secondary clinical signs of localized infection 41, 42 applying topical non-antibiotic agents after adequate debridement may be useful, perhaps by suppressing biofilm formation.
41 Table 3 summarizes our suggested approach to topical antimicrobial therapy for wounds. Cleaning and debriding of necrotic, sloughy or inflammatory material likely accelerates wound healing and is usually best achieved by mechanical means. Investigators are now seeking nonantibiotic approaches to killing bacteria in wounds. One recently described technique employs compounds that work by slowly releasing reactive oxygen radicals over a prolonged period. 43, 44 This can be accomplished with medical honey, which is highly antimicrobial, including against multiresistant organisms.
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Bone infection
Infection in bone typically develops by contiguous spread from overlying soft tissue. Osteomyelitis is usually more difficult to eradicate than soft tissue infection, but in some cases can be treated with prolonged ( 6 weeks) antibiotic therapy. Most authorities, however, prefer surgical removal of infected and necrotic bone, if possible. Initial antibiotic treatment of osteomyelitis is usually given intravenously, but in most cases this this can be quickly switched to (or in non-severe infections initiated with) oral therapy if there is an appropriate, bioavailable agent for the isolated pathogen(s). Bioavailability and bone penetration of most oral b-lactam antibiotics is limited, but that of fluoroquinolones, rifampicin, tetracyclines, oxazolidinones and clindamycin is good. 48, 49 Of note, therapy with certain agents (e.g. rifampicin, sodium fusidate, trimethoprim) must be in combination with another active agent (especially against S. aureus) to avoid rapid development of resistant strains.
Additional aspects of AMS in relation to wound management
Key stakeholders in local wound management and AMS programmes should optimally produce, or at least assess and oversee, guidelines for management of wound infections. A local quality improvement programme should assess key components of clinical management of wounds, such as regularly reviewing and reporting on the appropriateness of both outpatient and inpatient use of antibiotics. Sites should attempt to compare their results against their own previous performance as well as against other similar sites. Benchmarking can drive improvement in compliance with guidance documents. 50, 51 Quantitative review of prescribing is typically calculated using dispensing data, usually adjusted for activity. 52, 53 While these data do not describe individual patient prescribing, they provide information on antibiotic pressure and prescribing trends that help to monitor adverse antibiotic outcomes, particularly the development of resistance. 53 Qualitative review of antibiotic prescribing gives complementary information on clinical practice. Some key areas worthy of audit may include: frequency of examining for, and recording clinical signs of wound infection; recording specific infectious syndrome diagnoses; explaining the choice of an antibiotic regimen; compliance with local policies; and documenting the planned duration of therapy. 54, 55 Conducting a point prevalence survey can provide such information. 56 In parallel, there should be regular programmed reviews of antibiotic-associated adverse events, e.g. C. difficile infection or treatment-related acute kidney injury. 57 -59 Healthcare organizations and stewardship teams have found that using various process and outcomes measures for prescribing can improve performance. 51 In these areas, and most other aspects of AMS, nurses play a crucial role. 60, 61 Finally, regular programmed education and peer support are essential to ensure all members of the multidisciplinary team are familiar with local antimicrobial guidance and key surveillance data. Understanding and acceptance of the rationale for stewardship of antibiotics underpins compliance. Stewardship programmes should support easy and affordable access to highquality educational sessions and materials. Web-based educational packages on stewardship are becoming available for both medical and non-medical healthcare staff. 62 -65 There is much we still need to learn about caring for infected wounds, but the current state of knowledge is sufficient to offer some basic principles of management. Table 4 provides a brief summary of what we see as key opportunities for antimicrobial stewardship in wound management. 
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